PubRank

Michael P Vitek

Author PubWeight™ 79.35‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 2002 3.04
2 Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 2004 2.80
3 Solution NMR studies of the A beta(1-40) and A beta(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc 2004 2.79
4 Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation 2006 2.23
5 Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol 2011 1.97
6 APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003 1.80
7 Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci 2008 1.64
8 Protein nitration is mediated by heme and free metals through Fenton-type chemistry: an alternative to the NO/O2- reaction. Proc Natl Acad Sci U S A 2002 1.53
9 Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci 2011 1.43
10 Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol 2011 1.38
11 A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol 2005 1.34
12 Tau--an inhibitor of deacetylase HDAC6 function. J Neurochem 2009 1.27
13 Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci 2009 1.27
14 Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci U S A 2007 1.26
15 APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol Aging 2002 1.20
16 COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J Neurotrauma 2007 1.20
17 SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood 2011 1.18
18 The apolipoprotein E-mimetic peptide COG112 inhibits NF-kappaB signaling, proinflammatory cytokine expression, and disease activity in murine models of colitis. J Biol Chem 2010 1.14
19 Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. J Pharmacol Exp Ther 2006 1.14
20 Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res 2014 1.12
21 A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. Neurocrit Care 2006 1.09
22 The apolipoprotein E-mimetic peptide COG112 inhibits the inflammatory response to Citrobacter rodentium in colonic epithelial cells by preventing NF-kappaB activation. J Biol Chem 2008 1.08
23 The novel apolipoprotein E-based peptide COG1410 improves sensorimotor performance and reduces injury magnitude following cortical contusion injury. J Neurotrauma 2007 1.07
24 Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice. J Neurosci 2005 1.07
25 Pharmacogenomic effects of apolipoprotein e on intracerebral hemorrhage. Stroke 2008 1.07
26 Apolipoprotein E isoform mediated regulation of nitric oxide release. Free Radic Biol Med 2002 1.06
27 Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis 2009 1.06
28 Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease. PLoS One 2009 1.06
29 Traumatic brain injury exacerbates neurodegenerative pathology: improvement with an apolipoprotein E-based therapeutic. J Neurotrauma 2010 1.05
30 Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions. Pharmacogenomics 2007 1.05
31 A chemical perspective on the interplay between NO, reactive oxygen species, and reactive nitrogen oxide species. Ann N Y Acad Sci 2002 1.04
32 APOE genotype-specific differences in human and mouse macrophage nitric oxide production. J Neuroimmunol 2004 1.04
33 Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3beta cascade. FASEB J 2002 1.03
34 Sex steroids, APOE genotype and the innate immune system. Neurobiol Aging 2005 1.02
35 An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury. J Pharmacol Exp Ther 2010 1.02
36 Apolipoprotein-E allele-specific regulation of nitric oxide production. Ann N Y Acad Sci 2002 1.01
37 The tau N279K exon 10 splicing mutation recapitulates frontotemporal dementia and parkinsonism linked to chromosome 17 tauopathy in a mouse model. J Neurosci 2007 1.00
38 The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. J Alzheimers Dis 2008 0.99
39 Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage. Neurosurg Focus 2006 0.98
40 COG1410 improves cognitive performance and reduces cortical neuronal loss in the traumatically injured brain. J Neurotrauma 2009 0.97
41 Role of MAP1B in axonal retrograde transport of mitochondria. Biochem J 2006 0.97
42 A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma. J Vet Med Sci 2012 0.95
43 Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci 2011 0.94
44 Reelin signals survival through Src-family kinases that inactivate BAD activity. J Neurochem 2007 0.93
45 Use of a multiple-enzyme/multiple-reagent assay system to quantify activity levels in samples containing mixtures of matrix metalloproteinases. Biochemistry 2004 0.92
46 The APOE4 genotype alters the response of microglia and macrophages to 17beta-estradiol. Neurobiol Aging 2007 0.92
47 Cerebral cortical arteriolar angiopathy, vascular beta-amyloid, smooth muscle actin, Braak stage, and APOE genotype. Stroke 2008 0.91
48 Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid 2004 0.91
49 Intrathecal administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury. Neurosci Lett 2005 0.90
50 Cupric-amyloid beta peptide complex stimulates oxidation of ascorbate and generation of hydroxyl radical. Free Radic Biol Med 2004 0.90
51 Nitric oxide-mediated regulation of β-amyloid clearance via alterations of MMP-9/TIMP-1. J Neurochem 2012 0.89
52 Androgen-mediated immune function is altered by the apolipoprotein E gene. Endocrinology 2007 0.89
53 Apolipoprotein mimetic peptides: a new approach for the treatment of asthma. Front Pharmacol 2012 0.89
54 The apoE-mimetic peptide, COG1410, improves functional recovery in a murine model of intracerebral hemorrhage. Neurocrit Care 2012 0.89
55 Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice. J Neurosci 2008 0.87
56 Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity. J Biol Chem 2012 0.86
57 Function of tau protein in adult newborn neurons. FEBS Lett 2009 0.85
58 Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. BMC Gastroenterol 2012 0.85
59 COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia. J Neurosci Res 2009 0.84
60 ApolipoproteinE mimetic peptides improve outcome after focal ischemia. Exp Neurol 2012 0.83
61 COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat. Behav Brain Res 2010 0.83
62 Interaction between sex and apolipoprotein e genetic background in a murine model of intracerebral hemorrhage. Transl Stroke Res 2012 0.82
63 p53-dependent control of transactivation of the Pen2 promoter by presenilins. J Cell Sci 2009 0.82
64 The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from Alzheimer's disease-like pathological features. Neurodegener Dis 2012 0.79
65 The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma. J Vet Med Sci 2015 0.79
66 Selection of peptides binding to the amyloid b-protein reveals potential inhibitors of amyloid formation. Amyloid 2005 0.79
67 Human apolipoprotein E2 promotes parenchymal amyloid deposition and neuronal loss in vasculotropic mutant amyloid-β protein Tg-SwDI mice. J Alzheimers Dis 2012 0.78
68 mNos2 deletion and human NOS2 replacement in Alzheimer disease models. J Neuropathol Exp Neurol 2014 0.78
69 ApoE mimetic ameliorates motor deficit and tissue damage in rat spinal cord injury. J Neurosci Res 2014 0.76
70 NPY and chronic neurodegenerative disease. EXS 2006 0.76
71 The impact of human and mouse differences in NOS2 gene expression on the brain's redox and immune environment. Mol Neurodegener 2014 0.76